# Fludarabine, Cytarabine, Topotecan in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

> **NCT00488709** · PHASE4 · COMPLETED · sponsor: **PETHEMA Foundation** · enrollment: 47 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Topotecan
- **DRUG:** Fludarabine
- **DRUG:** Cytarabine

## Key facts

- **NCT ID:** NCT00488709
- **Lead sponsor:** PETHEMA Foundation
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-05
- **Primary completion:** —
- **Final completion:** 2007-04
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2008-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00488709

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00488709, "Fludarabine, Cytarabine, Topotecan in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00488709. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*